OBJECTIVE: The genetic association of interferon regulatory factor 5 (IRF5) with systemic lupus erythematosus (SLE) susceptibility has been convincingly established. To gain understanding of the effect of IRF5 variation in individuals without SLE, a study was undertaken to examine whether such genetic variation predisposes to activation of the interferon alpha (IFNalpha) pathway. METHODS: Using a computer simulated approach, 14 single nucleotide polymorphisms (SNPs) and haplotypes of IRF5 were tested for association with mRNA expression levels of IRF5, IFNalpha and IFN-inducible genes and chemokines in lymphoblastoid cell lines (LCLs) from individuals of European (CEU), Han Chinese (CHB), Japanese (JPT) and Yoruba Nigerian (YRI) backgrounds. IFN-inducible gene expression was assessed in LCLs from children with SLE in the presence and absence of IFNalpha stimulation. RESULTS: The major alleles of IRF5 rs13242262 and rs2280714 were associated with increased IRF5 mRNA expression levels in the CEU, CHB+JPT and YRI samples. The minor allele of IRF5 rs10488631 was associated with increased IRF5, IFNalpha and IFN-inducible chemokine expression in CEU (p(c)=0.0005, 0.01 and 0.04, respectively). A haplotype containing these risk alleles of rs13242262, rs10488631 and rs2280714 was associated with increased IRF5, IFNalpha and IFN-inducible chemokine expression in CEU LCLs. In vitro studies showed specific activation of IFN-inducible genes in LCLs by IFNalpha. CONCLUSIONS: SNPs of IRF5 in healthy individuals of a number of ethnic groups were associated with increased mRNA expression of IRF5. In European-derived individuals, an IRF5 haplotype was associated with increased IRF5, IFNalpha and IFN-inducible chemokine expression. Identifying individuals genetically predisposed to increased IFN-inducible gene and chemokine expression may allow early detection of risk for SLE.
OBJECTIVE: The genetic association of interferon regulatory factor 5 (IRF5) with systemic lupus erythematosus (SLE) susceptibility has been convincingly established. To gain understanding of the effect of IRF5 variation in individuals without SLE, a study was undertaken to examine whether such genetic variation predisposes to activation of the interferon alpha (IFNalpha) pathway. METHODS: Using a computer simulated approach, 14 single nucleotide polymorphisms (SNPs) and haplotypes of IRF5 were tested for association with mRNA expression levels of IRF5, IFNalpha and IFN-inducible genes and chemokines in lymphoblastoid cell lines (LCLs) from individuals of European (CEU), Han Chinese (CHB), Japanese (JPT) and Yoruba Nigerian (YRI) backgrounds. IFN-inducible gene expression was assessed in LCLs from children with SLE in the presence and absence of IFNalpha stimulation. RESULTS: The major alleles of IRF5rs13242262 and rs2280714 were associated with increased IRF5 mRNA expression levels in the CEU, CHB+JPT and YRI samples. The minor allele of IRF5rs10488631 was associated with increased IRF5, IFNalpha and IFN-inducible chemokine expression in CEU (p(c)=0.0005, 0.01 and 0.04, respectively). A haplotype containing these risk alleles of rs13242262, rs10488631 and rs2280714 was associated with increased IRF5, IFNalpha and IFN-inducible chemokine expression in CEU LCLs. In vitro studies showed specific activation of IFN-inducible genes in LCLs by IFNalpha. CONCLUSIONS: SNPs of IRF5 in healthy individuals of a number of ethnic groups were associated with increased mRNA expression of IRF5. In European-derived individuals, an IRF5 haplotype was associated with increased IRF5, IFNalpha and IFN-inducible chemokine expression. Identifying individuals genetically predisposed to increased IFN-inducible gene and chemokine expression may allow early detection of risk for SLE.
Authors: Ronan J Walsh; Sek Won Kong; Yihong Yao; Bahija Jallal; Peter A Kiener; Jack L Pinkus; Alan H Beggs; Anthony A Amato; Steven A Greenberg Journal: Arthritis Rheum Date: 2007-11
Authors: Emily C Baechler; Franak M Batliwalla; George Karypis; Patrick M Gaffney; Ward A Ortmann; Karl J Espe; Katherine B Shark; William J Grande; Karis M Hughes; Vivek Kapur; Peter K Gregersen; Timothy W Behrens Journal: Proc Natl Acad Sci U S A Date: 2003-02-25 Impact factor: 11.205
Authors: K Shimane; Y Kochi; R Yamada; Y Okada; A Suzuki; A Miyatake; M Kubo; Y Nakamura; K Yamamoto Journal: Ann Rheum Dis Date: 2008-04-13 Impact factor: 19.103
Authors: Silvia N Kariuki; Kyriakos A Kirou; Emma J MacDermott; Lilliana Barillas-Arias; Mary K Crow; Timothy B Niewold Journal: J Immunol Date: 2009-01-01 Impact factor: 5.422
Authors: A-K Abelson; A M Delgado-Vega; S V Kozyrev; E Sánchez; R Velázquez-Cruz; N Eriksson; J Wojcik; M V P Linga Reddy; G Lima; S D'Alfonso; S Migliaresi; V Baca; L Orozco; T Witte; N Ortego-Centeno; H Abderrahim; B A Pons-Estel; C Gutiérrez; A Suárez; M F González-Escribano; J Martin; M E Alarcón-Riquelme Journal: Ann Rheum Dis Date: 2008-11-19 Impact factor: 19.103
Authors: Lynda Bennett; A Karolina Palucka; Edsel Arce; Victoria Cantrell; Josef Borvak; Jacques Banchereau; Virginia Pascual Journal: J Exp Med Date: 2003-03-17 Impact factor: 14.307
Authors: K Santana-de Anda; D Gómez-Martín; A E Monsivais-Urenda; M Salgado-Bustamante; R González-Amaro; J Alcocer-Varela Journal: Clin Exp Immunol Date: 2014-12 Impact factor: 4.330
Authors: Ruth-Anne Langan Pai; Alberto Sada Japp; Michael Gonzalez; Rozena F Rasheed; Mariko Okumura; Daniel Arenas; Sheila K Pierson; Victoria Powers; Awo Akosua Kesewa Layman; Charlly Kao; Hakon Hakonarson; Frits van Rhee; Michael R Betts; Taku Kambayashi; David C Fajgenbaum Journal: JCI Insight Date: 2020-05-07